Hostname: page-component-5c6d5d7d68-lvtdw Total loading time: 0 Render date: 2024-08-07T20:13:37.486Z Has data issue: false hasContentIssue false
  • English
  • Français

The Ethnopharmacology of Atypical Antipsychotics

Published online by Cambridge University Press:  07 November 2014

L. DiAnne Bradford
L. DiAnne Bradford*
Affiliation:
Dr. Bradford is Professor in the Departments of Psychiatry and Medicine at, Morehouse School of Medicine, in Atlanta, Georgia
*
L. DiAnne Bradford, PhD, Department of Psychiatry, Morehouse School of Medicine, 720 Westview Dr. SW, Atlanta, GA 30310-1495; Tel: 404-756-5033; Fax: 404-756-5034; E-mail: bradford@msm.edu.
Get access Rights & Permissions [Opens in a new window]

Abstract

Since the risk of antipsychotic-induced adverse events is often related to plasma drug concentrations, factors that influence the metabolic transformation of these agents can substantially influence this risk. The cytochrome P450 (CYP) enzyme system, particularly CYP2D6, is very important for the metabolism of many typical and atypical antipsychotic agents. However, there is substantial ethnic/racial pharmacogenetic variability in the phenotypic (ie, metabolic rate) or genotypic (ie, presence of functional or nonfunctional alleles) expression of these enzyme systems. Caucasians have a bimodal distribution of CYP2D6 enzyme activity, with individuals classified either as extensive or poor metabolizers. In contrast, while there are few poor metabolizers among people of Asian descent, a substantial proportion of this population exhibits an intermediate rate of metabolism. African American populations also have a substantial number of intermediate metabolizers, and about the same number of poor metabolizers as Caucasians. Mexican Americans may have a slightly higher metabolic rate than other ethnic groups. Numerous studies have demonstrated that CYP2D6 metabolic status influences the clearance of conventional and atypical antipsychotics. African Americans and Asians, with CYP2D6 phenotypes or genotypes indicative of poor metabolizers, frequently exhibit significantly higher plasma drug concentrations and longer half-lives compared to extensive metabolizers. Importantly, this increased drug exposure is associated with an increased risk of extrapyramidal symptoms. Data on metabolic polymorphism of antipsychotics are lacking among African Americans. There are also some data suggesting that genetic polymorphism can influence the risk of antipsychotic-induced weight gain. These findings highlight the need to consider race/ethnicity when prescribing, dosing, and monitoring antipsychotic agents.

Type
Research Article
Information
CNS Spectrums , Volume 10 , Issue S2 , 2005 , pp. 6 - 12
Copyright
Copyright © Cambridge University Press 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Scordo, MG, Spina, E, Romeo, P, et al.CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients. Eur J Clin Pharmacol. 2000;56:679–683.CrossRefGoogle ScholarPubMed
2.Schillevoort, I, de Boer, A, van der Weide, J, et al.Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study. Pharmacogenetics. 2002;12:235–240.Google Scholar
3.Gonzalez, FJ. The molecular biology of cytochrome P450s. Pharmacol Rev. 1989;40:243–288.Google Scholar
4.Brockmoller, J, Kirchheiner, J, Meisel, C, Roots, I. Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment. Pharmacogenomics. 2000;1:125–151.Google Scholar
5.Eichelbaum, M, Gross, AS. The genetic polymorphism of debrisoquine/sparteine metabolism—clinical aspects. Pharmacol Ther. 1990;46:377–394.Google Scholar
6.Wilkinson, GR, Guengerich, FP, Branch, RA. Genetic polymorphism of S-mephenytoin hydroxylation. Pharmacol Ther. 1989;43:53–76.Google Scholar
7.Wood, AJ, Zhou, HH. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet. 1991;20:350–373.CrossRefGoogle ScholarPubMed
8.Kalow, W. Interethnic variation of drug metabolism. TiPS. 1991;12:102–107.Google Scholar
9.Gaedigk, A, Bradford, LD, Marcucci, KA, Leeder, JS. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther. 2002;72:76–89.CrossRefGoogle ScholarPubMed
10.Hardman, JG, Limbird, LE, eds. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill; 1996.Google Scholar
11.Physician’s Desk Reference. 2003. 57th ed. Montvale, NJ: Medical Economics.Google Scholar
12.Bradford, LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3:229–243.CrossRefGoogle ScholarPubMed
13.Bradford, LD, Gaedigk, A, Leeder, JS. High frequency of CYP2D6 poor and “intermediate” metabolizers in black populations: a review and preliminary data. Psychopharmacol Bull. 1998;34:797–804.Google ScholarPubMed
14.Wan, Y-J Y, Poland, RE, Han, G, et al.Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in Southern California. Pharmacogenetics. 2001;11:489–499.CrossRefGoogle ScholarPubMed
15.Mendoza, R, Wan, Y-J, Poland, RE, et al.CYP2D6 polymorphism in a Mexican American population. Clin Pharmacol Ther. 2001;70:552–560.Google Scholar
16.Gaedigk, A, Gotschall, RR, Forbes, NS, Simon, SD, Kearns, GL, Leeder, JS. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics. 1999;9:669–682.CrossRefGoogle ScholarPubMed
17.Bock, KW, Schrenk, D, Foster, A, et al.The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics. 1994;4:209–218.Google Scholar
18.Lin, KM, Anderson, D, Poland, RE. Ethnicity and psychopharmacology. Bridging the gap. Psychiatr Clin North Am. 1995;18:635–647.Google Scholar
19.Tateishi, T, Chida, M, Ariyoshi, N, Mizorogi, Y, Kamataki, T, Kobayashi, S. Analysis of the CYP2D6 gene in relation to dextromethorphan O-demethylation capacity in a Japanese population. Clin Pharmacol Ther. 1999;65:570–575.Google Scholar
20.Dahl-Puustinen, M-L, Liden, A, Alm, C, Nordin, C, Bertilsson, L. Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings. Clin Pharmacol Ther. 1989;46:78–81.CrossRefGoogle ScholarPubMed
21.Dahl, ML, Ekqvist, B, Widen, J, Bertilsson, L. Disposition of the neuroleptic zuclopenthixol cosegregates with the polymorphic hydroxylation of debrisoquine in humans. Acta Psychiatr Scand. 1991;84:99–102.Google Scholar
22.von Bahr, C, Movin, G, Nordin, C, et al.Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther. 1991;49:234–240.Google Scholar
23.Llerena, A, Alm, C, Dahl, ML, Ekqvist, B, Bertilsson, L. Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther Drug Monit. 1992;14:92–97.Google Scholar
24.Llerena, A, Dahl, ML, Ekqvist, B, Bertilsson, L. Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther Drug Monit. 1992;14:261–264.CrossRefGoogle ScholarPubMed
25.Berecz, R, de la Rubia, A, Dorado, P, Fernandez-Salguero, P, Dahl, M-L, Llerena, A. Thioridazine steady-state plasma concentrations are influenced by tobacco smoking and CYP2D6, but not by the CYP2C9 genotype. Eur J Clin Pharmacol. 2003;59:45–50.CrossRefGoogle Scholar
26.Llerena, A, Berecz, R, de la Rubia, A, Norberto, MJ, Benitez, J. Use of the mesoridazine/thioridazine ratio as a marker for CYP2D6 enzyme activity. Ther Drug Monit. 2000;22:397–401.Google Scholar
27.Linnet, K, Wiborg, O. Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism. Clin Pharmacol Ther. 1996;60:41–47.Google Scholar
28.Linnet, K, Wiborg, O. Influence of CYP2D6 genetic polymorphism on ratios of steady-state serum concentration to dose of the neuroleptic zuclopenthixol. Ther Drug Monit. 1996;18:629–634.Google Scholar
29.Jerling, M, Dahl, M-L, Aberg-Wistedt, A, et al.The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol. Clin Pharmacol Ther. 1996;59:423–428.Google Scholar
30.Jaanson, P, Marandi, T, Kiivet, R-A, et al.Maintenance therapy with zuclopenthixol decanoate: associations between plasma concentrations, neurological side effects and CYP2D6 gentoype. Psychopharmacology. 2002;162:67–73.Google Scholar
31.Eap, CB, Guentert, TW, Schaublin-Loidl, M, et al.Plasma levels of the enantiomers of thioridazine, thioridazine 2-sulfoxide, thioridazine 2-sulfone, and thioridazine 5-sulfoxide in poor and extensive metabolizers of dextromethorphan and mephenytoin. Clin Pharmacol Ther. 1996;59:322–331.Google Scholar
32.Baumann, P, Meyer, JW, Amey, M, et al.Dextromethorphan and mephenytoin phenotyping of patients treated with thioridazine or amitriptyline. Ther Drug Monit. 1992;14:1–8.CrossRefGoogle ScholarPubMed
33. Abilify® [package insert]. Princeton, NJ: Bristol-Myers Squibb Co; 2004.Google Scholar
34.Huang, M-L, Van Peer, A, Woestenborghs, R, et al.Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther. 1993;54:257–268.Google Scholar
35.Ereshefsky, L, Lacombe, S. Pharmacological profile of risperidone. Can J Psychiatry. 1993;38(suppl 3):S80–S88.Google Scholar
36.Scordo, MG, Spina, E, Facciola, G, Avenoso, A, Johansson, I, Dahl, M-L. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone. Psychopharmacology. 1999;147:300–305.Google Scholar
37.Berecz, R, Llerena, A, de la Rubia, A, et al.Relationship between risperidone and 9-hydroxy-risperidone plasma concentrations and CYP2D6 enzyme activity in psychiatric patients. Pharmacopsychiatry. 2002;35:231–234.Google Scholar
38.Yasui-Furukori, N, Hidestrand, M, Spina, E, Facciola, G, Scordo, MG, Tybring, G. Different enantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes. Drug Metabol Dispos. 2001;29:1263–1268.Google Scholar
39.Haag, S, Spigset, O, Lakso, HA, Dahlqvist, R. Olanzapine disposition in humans is unrelated to CYP1A2 and CYP2D6 phenotypes. Eur J Clin Pharmacol. 2001;57:493–497.Google Scholar
40.Lin, K-M, Finder, E. Neuroleptic dosage for Asians. Am J Psychiatry. 1983;4:490–491.Google Scholar
41.Yamamoto, J, Fung, D, Lo, S, Reece, S. Psychopharmacology for Asian Americans and Pacific Islanders. Psychopharmacol Bull. 1979;15:29–31.Google Scholar
42.Potkin, SG, Shen, Y, Pardes, H, et al.Haloperidol concentrations elevated in Chinese patients. Psychiatry Res. 1984;12:167–172.Google Scholar
43.Suzuki, A, Otani, K, Mihara, K, et al.Effects of the CYP2D6 genotype on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese schizophrenic patients. Pharmacogenetics. 1997;7:415–418.Google Scholar
44.Mihara, K, Suzuki, A, Kondo, T, et al.Effect of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia. Clin Pharmacol Ther. 1999;65:291–294.Google Scholar
45.Someya, T, Suzuki, Y, Shimoda, K, et al.The effect of cytochrome P450 2D6 genotypes on haloperidol metabolism: a preliminary study in a psychiatric population. Psych Clin Neurosci. 1999;53:593–597.Google Scholar
46.Roh, H-K, Chung, J-Y, Oh, D-Y, et al.Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients. Br J Clin Pharmacol. 2001;52:265–271.Google Scholar
47.Ohara, K, Tanabu, S, Ishibashi, K, Ikemoto, K, Yoshida, K, Shibuya, H. Effects of age and the CYP2D6*10 allele on the plasma haloperidol concentration/dose ratio. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:347–350.Google Scholar
48.Yasui-Furukori, N, Kondo, T, Mihara, K, et al.Lack of correlation between the steady-state plasma concentrations of haloperidol and risperidone. J Clin Pharmacol. 2002;42:1083–1088.Google ScholarPubMed
49.Lane, H-Y, Hu, O Y-P, Jann, MW, Deng, H-C, Lin, H-N, Chang, W-H. Dextromethorphan phenotyping and haloperidol disposition in schizophrenic patients. Psychiatr Res. 1997;69:105–111.Google Scholar
50.Shibata, N, Ohnuma, T, Baba, H, Shimada, H, Takahashi, T, Arai, H. Genetic association between cytochrome P-450 2D6 gene polymorphism and plasma concentration of haloperidol in Japanese schizophrenics. Psychiatr Genet. 1999;9:145–148.Google Scholar
51.Shimoda, K, Morita, S, Yokono, A, et al.CYP2D6*10 alleles are not the determinant of plasma haloperidol concentrations in Asian patients. Ther Drug Monit. 2000;22:392–396.Google Scholar
52.Roh, H-K, Kim, C-E, Chung, W-G, Park, C-S, Svensson, J-O, Bertilsson, L. Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients. Eur J Clin Pharmacol. 2001;57:671–675.Google Scholar
53.Pollock, BG, Mulsant, BH, Sweet, RA, Rosen, J, Altieri, LP, Perel, JM. Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. Psychopharmacol Bull. 1995;31:327–332.Google Scholar
54.Arthur, H, Dahl, M-L, Siwers, B, Sjogvist, F. Polymorphic drug metabolism in schizophrenic patients with tardive dyskinesia. J Clin Psychopharmacol. 1995;15:211–216.Google Scholar
55.Vandel, P, Haffen, E, Vandel, S, et al.Drug extrapyramidal side effects. CYP2D6 genotypes and phenotypes. Eur J Clin Pharmacol. 1999;55:659–665.Google Scholar
56.Ellingrod, VL, Schultz, SK, Arndt, S. Association between cytochrome P4502D6 (CYP2D6) genotype, antipsychotic exposure, and abnormal movement scale (AIMS) score. Psychiatr Genet. 2000;10:9–11.Google Scholar
57.Ellingrod, VL, Schultz, SK, Arndt, S. Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6. Pharmacotherapy. 2002;22:1416–1419.Google Scholar
58.Andreassen, OA, MacEwan, T, Gulbrandsen, A-K, McCreadie, RG, Steen, VM. Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients. Psychopharmacology. 1997;131:174–179.Google Scholar
59.Armstrong, M, Daly, AK, Blennerhassett, R, Ferrier, N, Idle, JR. Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. Br J Psychiatry. 1997;170:23–26.Google Scholar
60.Lohmann, PL, Bagli, M, Krauss, H, et al.CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients. Pharmacopsychiatry. 2003;36:73–78.Google Scholar
61.Kapitany, T, Meszaros, K, Lenzinger, E, et al.Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophrenia Res. 1998;32:101–106.Google Scholar
62.Spina, E, Ancione, M, Di Rosa, AE, Meduri, M, Caputi, AP. Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects. Eur J Clin Pharmacol. 1992;42:347–348.Google Scholar
63.Topic, E, Stefanovic, M, Ivanisevic, AM, Blazinic, F, Culav, J, Skocilic, A. CYP2D6 genotyping in patients on psychoactive drug therapy. Clin Chem Lab Med. 2000;38:921–927.Google Scholar
64.Binder, RL, Levy, R. Extrapyramidal reactions in Asians. Am J Psychiatry. 1981;138:1243–1244.Google Scholar
65.Binder, RL, Kazamatsuri, H, Nishimura, T, McNiel, DE. Tardive dyskinesia and neuroleptic-induced parkinsonism in Japan. Am J Psychiatry. 1987;144:1494–1496.Google Scholar
66.Sramek, JJ, Sayles, MA, Simpson, GM. Neuroleptic dosage for Asians: a failure to replicate. Am J Psychiatry. 1986;143:535–536.Google ScholarPubMed
67.Lam, LCW, Garcia-Barcelo, MM, Ungvari, GS, et al.Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients. Pharmacopsychiatry. 2001;34:238–241.Google Scholar
68.Nikoloff, D, Shim, J-C, Fairchild, M, et al.Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics. Pharmacogenomics J. 2002;2:400–407.Google Scholar
69.Strakowski, SM, Shelton, RC, Kolbrener, ML. The effects of race and comorbidity on clinical diagnosis in patients with psychosis. J Clin Psychiatry. 1993;54:96–102.Google ScholarPubMed
70.Lawson, WB, Hepler, N, Holladay, J, Cuffel, B. Race as a factor in inpatient and outpatient admissions and diagnosis. Hosp Comm Psychiatry. 1994;45:72–74.Google Scholar
71.DelBello, MP, Lopez-Larson, MP, Soutullo, CA, Strakowski, SM. Effects of race on psychiatric diagnosis of hospitalized adolescents: a retrospective chart review. J Child Adolesc Psychopharmacol. 2001;11:95–103.Google Scholar
72.Opolka, JL, Rascati, K, Brown, CM, Gibson, JP. Ethnicity and schizophrenia medication choice. Presented at the Annual Meeting for the American Psychiatric Association; May 17-22, 2003; San Francisco, CA. Abstract NR 551.Google Scholar
73.Tami, M, et al.Schizophrenia care and the assessment program: treatment by race. Presented at the Annual Meeting of the American Psychiatric Association; May 18-23, 2002; Philadelphia, PA. Abstract NR 360.Google Scholar
74.Morganstern, H, Glazer, WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Arch Gen Psychiatry. 1993;50:723–733.Google Scholar
75.este, DV, Lindamer, LA, Evans, J, Lacro, JP. Relationship of ethnicity and gender to schizophrenia and pharmacology of neuroleptics. Psychopharmacol Bull. 1996;32:243–251.Google Scholar
76.Reynolds, GP, Zhang, Z-J, Zhang, X-B. Association of antipsychotic drug-induced weight gain with a 5-HT2C receptor gene polymorphism. Lancet. 2002;359:2086–2087.Google Scholar
77.Ellingrod, VL, Miller, D, Schultz, SK, Wehring, H, Arndt, S. CYP2D6 polymorphisms and atypical antipsychotic weight gain. Psychiatr Genet. 2002;12:55–58.Google Scholar
78.Gaedigk, A, Ndjountche, L, Gaedigk, R, Leeder, JS, Bradford, LD. Discovery of novel nonfunctional cytochrome P450 2D6 allele, CYP2D642, in African American subjects. Clin Pharmacol Ther. 2003;73:575–576.CrossRefGoogle ScholarPubMed